Shanghai Jianxin Biomedical Technology

Shanghai Jianxin Biomedical Technology Co., Ltd., which also operates under the name L&L Biopharma, is a clinical-stage biotechnology firm with a sharp focus on oncology. The company was registered on October 29, 2015, and commenced full operations in June 2016, later earning recognition as a national high-tech enterprise in 2020. Its founder, Liu Jiajian, holds a Ph.D. in molecular biology from Nankai University, providing a strong scientific foundation for the company's research-intensive direction.

The company directs its resources toward the preclinical and clinical development of novel drugs for tumor immunotherapy. A core area of its work is creating first-in-class (FIC) and best-in-class (BIC) biopharmaceutical products to address significant unmet needs in cancer treatment. Specifically, L&L Biopharma concentrates on developing bispecific and trispecific antibodies for patients who do not respond to or have developed resistance to existing PD-1/PD-L1 antibody therapies. The business model involves advancing these proprietary drug candidates through the early phases of clinical trials and then pursuing out-licensing agreements and partnerships with larger pharmaceutical companies for further development and commercialization. The company is currently in a Series B funding stage, with investors including Panlin Capital, Qiaojing Capital, and Topping Capital.

L&L Biopharma's pipeline includes several promising candidates. Two of its bispecific antibody projects, BIS5 and BIS2, are currently in Phase I clinical studies. BIS5 is a dual-antibody product designed for lung cancer treatment, targeting patients for whom PD-1 treatments have been ineffective. Another key asset, LB1410, is a PD-1/TIM-3 bispecific antibody intended for solid tumors like lung and esophageal cancer that are unresponsive to anti-PD-1/PD-L1 therapies. This product is undergoing Phase I trials and has been approved for a combination trial with another of the company's products. The company also has LB4330, a dual-functional immunotherapy product for cancers such as pancreatic and gastric cancer, which has received IND approval in both China and the United States. The firm possesses multiple technology platforms for antibody discovery, including those for monoclonal, bispecific, and multispecific antibodies, as well as computer-aided humanization technology.

Keywords: L&L Biopharma, clinical-stage biotechnology, tumor immunotherapy, oncology, bispecific antibodies, trispecific antibodies, PD-1 resistance, first-in-class, best-in-class, antibody drug development, cancer therapy, biopharmaceuticals, preclinical research, clinical trials, out-licensing, LB1410, BIS5, LB4330, monoclonal antibodies, pharmaceutical research, immuno-oncology, cancer treatment, drug development pipeline, Series B, venture capital